Innate Pharma’s Next-Gen ANKET® IPH6501 Highlighted in Science Immunology
Innate Pharma announced preclinical data demonstrating the potential of IPH6501, its proprietary NK cell engager, for B-cell non-Hodgkin lymphoma...
Enhancing Patient Engagement in Clinical Trials: Insights from Medable
In a recent discussion with Jena Daniels, VP of Patient Success at Medable, we explored the company’s recognition as...
Boston Pharmaceuticals Positive Phase 2 NASH Data at AASLD 2024
Boston Pharmaceuticals announced positive Phase 2 study results for efimosfermin alfa, a long-acting FGF21 analogue, in patients with stage...
VIR Biotech HBV Combination Therapy Shows Promise in March Study
Vir Biotechnology announced positive end-of-treatment results from Part B of its MARCH Phase 2 clinical study. This study is...
CHMP Positive on Opdivo + Yervoy for MSI-H/dMMR mCRC
Bristol Myers Squibb (BMS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...
Gilead Livdelzi Shows Sustained Efficacy, Long-Term Safety in PBC Management
Gilead Sciences recently released promising interim data from the Phase 3 ASSURE study on Livdelzi (seladelpar) for primary biliary...
Zura Bio Submits Scleroderma Drug Protocol for FDA Phase 2 Study
Zura Bio, a clinical-stage immunology company, has submitted a Phase 2 study protocol to the FDA for tibulizumab. This...
Lineage Cell Therapeutics Q3 2024 Results & Update
Lineage Cell Therapeutics announced its third quarter 2024 financial and operating results, highlighting progress in its allogeneic cell therapy...
Perspectum’s FDA Grant for Rare Disease Biomarker Evaluation
Perspectum, a medical imaging technology company, has received a substantial research grant from the U.S. Food and Drug Administration...
Cancer Patient Rights: Expanding Lifesaving Care in Illinois
A coalition of prominent cancer organizations, alongside Illinois lawmakers, is advocating for the Illinois Cancer Patients Bill of Rights....